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Abstract. A consensus development meeting was held to evaluate whether or not in the Netherlands all requirements were
fulfilled for implementation of population screening with FOBT for colorectal cancer, or whether consensus was present that
fulfilment by additional research or organisational actions could be obtained within 2–3 years. There was consensus that all
classical Wilson and Jungner (1968) criteria, and six additional ones added more recently, had already been fulfilled or could be
fulfilled within 2–3 years. Consequently, it was concluded that a national population screening for colorectal cancer should be
implemented and carried out in the Netherlands in line with current national and European cancer screening programmes. A list
of organisational actions to be taken was established. Research that is needed before the actual national launch of the screening
within 2–3 years has been defined. Priorities have to be set for research and organisational actions for the coming 2–3 years
for the implementation of population screening. In addition, research suggestions have been defined for the next 10–15 years
for evaluation and/or improvement of implemented FOBT screening, and for future screening methodology. It was considered
essential that infrastructure for future research would be embedded in the screening programme. A project group to arrange this
should be formed.
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General introduction
The debate on the introduction of population screen-
ing for colorectal cancer (CRC) in the Netherlands has
been going on for some time. As yet, no political de-
cision to introduce population screening for CRC has
been taken. The Ministry of Health, Welfare and Sport
however has shown interest and investigates the possi-
bilities for the introduction of population screening.
ZonMw had already commissioned a project in
preparation for the design of a large feasibility study
on population screening for CRC. This resulted in the
publication of the Cocast report in 2003 [1]. Since
then, ZonMw has received several grant applications
for further development of population screening for
CRC and research into the possibility of population
screening using methods other than FOBT in the fu-
ture. It was obvious that in the absence of a clear
agenda, grant applications were very diverse and a di-
vergent rather than convergent situation was emerging.
It was concluded that in order to facilitate program-
ming at ZonMw, goals for research and development
studies need to be defined.
This has resulted in a timely plan to arrange a con-
sensus development procedure, starting mid 2004, to
discuss and define a road map for future develop-
ments and investments. The choice of FOBT for pop-
ulation screening appeared most obvious as was sup-
ported by international publications [2,4,6,7,9,13] and
in the Netherlands by recommendations of the Health
Council of the Netherlands [5], the Dutch Cancer So-
ciety [8], the Cocast group [1], and the ‘Nationaal Pro-
gramma Kankerbestrijding’ (the Dutch programme for
cancer control) [11].
Hence, the choice for FOBT was a pre-consensus
issue and this has guided decisions on grant prior-
ities. Accordingly, ZonMw’s Prevention Programme
has approved a grant application for a FOBT imple-
mentation study of screening using the FOBT method
(Amsterdam–Nijmegen trial). The results of this im-
plementation project are expected in the year 2007 and
should help to define a protocol for population screen-
ing that is tailored to the situation in the Netherlands.
In September 2004 the Dutch Cancer Society pub-
lished a Signalling Report entitled ‘Early detection
of CRC: reduction in mortality by population-based
screening’ [8]. The report lists the techniques avail-
able for population screening for CRC, and the results
of population screening in other countries. Using this
information, it provides recommendations for the im-
plementation of population screening for CRC in the
Netherlands. Its main recommendation is that popu-
lation screening for CRC should be introduced in the
Netherlands in the near future in several trial centres.
For population screening to commence there must be
agreement between all parties. A meeting at which the
problems and priorities can be identified from various
perspectives would accelerate and improve the intro-
duction of population screening.
On November 4th, 2004, the report of the ‘Nation-
aal Programma Kankerbestrijding’ [11] was presented
to the minister of Health, Welfare and Sport, Hans
Hoogervorst. The report recommends that the Ministry
of Health, Welfare and Sport takes control of matters
and initiates a decision-making process on the intro-
duction of population screening for CRC before the
end of the year, according to a step-by-step plan set-
ting out clear deadlines. In his speech, the minister an-
nounced that his Ministry is studying the possibility of
introducing population screening for CRC.
In the Netherlands, we thus find ourselves at the
beginning of a process that might eventually lead to
the introduction of population screening for CRC. It
is fortunate that almost without exception all organisa-
tions are in favour of and suggest introducing screen-
ing for CRC. ZonMw and The Dutch Cancer Society
joined forces and took the lead in organising a consen-
sus development meeting. The consensus development
meeting is instrumental in defining research (or deci-
sions) (a) in the short term that are necessary to finalise
a protocol for FOBT-screening, and (b) in the longer
term for the further development of the screening pro-
gramme, either concerning improvement of the present
approach and/or concerning new technologies. In ad-
dition, the participation of most, if not all, parties in-
volved in screening and future research will stimulate
communication, identification of hurdles, commitment
and effective implementation. Hopefully it will result
in clear understanding of future research priorities and
provide indications for sources of programme funding.
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Overview of the consensus procedure
ZonMw and The Dutch Cancer Society have opted
for a consensus development procedure (CDP) accord-
ing to a structure described before [12] because the par-
ties involved in the introduction of population screen-
ing for CRC are diverse in terms of organisation, fi-
nancing, responsibilities, and may have conflicting in-
terests. A CDP is a systematic approach to gaining
awareness of each other’s interests, and obtaining clar-
ity on each other’s intentions and efforts and on the
possibilities for introducing population screening. The
idea is for parties to agree as much as possible and to
expose any differences of opinion.
The CDP discussed all issues on which agreement
(consensus) must be reached in order for population
screening to be introduced, according to a structured
approach for which extended criteria of Wilson and
Jungner [3,10,14] for population screening have been
used as a checklist.
First, in the spring of 2004, representatives from
many parties were interviewed in order to define topics
and specific questions to be answered and additional
parties needed to reach a consensus. The CDP was fi-
nalised by bringing together all the stakeholders at a
meeting in February 2005 to discuss the topics and as-
sess the degree of consensus that exists among them.
During the CDP, issues have been discussed that
might hamper the introduction of population screen-
ing for CRC, and ways of ensuring that it will run
smoothly. The outcome of these discussions will guide
ZonMw in its decision regarding what type of research
it should support for the purpose of introducing popu-
lation screening in the coming 2–3 years. Both ZonMw
and the Dutch Cancer Society are keen on solving
any practical and organisational problems connected
with population screening for CRC. An organisation
for CRC screening using FOBT needs to be set up.
It is of paramount importance that the results from
ZonMw-financed research can be implemented. For
the Dutch Cancer Society, the organisation of CRC
screening is important in view of its position that popu-
lation screening should commence as soon as possible.
The CDP has additionally identified research issues
that may accompany screening implementation, re-
search focusing on aspects of the screening that might
be improved and finally, research to evaluate additional
or new screening technologies that may be added to
the FOBT infrastructure or replace it on the long run.
The planning of the infrastructure of the screening was
also discussed. The requirements for the databases and
biobanks to enable a cost-effective and time-effective
infrastructure for the mentioned research were defined.
The CDP has produced four products:
(1) An assessment of the extended Wilson and
Jungner criteria in relation to CRC screening.
(2) An inventory of existing knowledge and gaps
in the knowledge, and in existing organisational
infrastructure.
(3) Solutions for unresolved questions (decisions or
dedicated research) and a list of organisational
actions to be taken.
(4) Forecast and infrastructure of future research for
screening and possible improvements.
Together, these products constitute a road map towards
a nationwide CRC screening programme in the Nether-
lands and its continuous improvement.
The expected timelines are as follows:
– 2005: Political decision on the introduction of
population screening for CRC.
– Up to 2007: Trial implementation and implemen-
tation study of screening using the FOBT method
(Amsterdam–Nijmegen trial).
– Up to 2007: Further research and organisation
for the purpose of the introduction of population
screening.
– Short-medium term: Research for the purpose of
improving the quality of the population-screening
programme.
– Short-long term: Research for the purpose of
future changes/improvements to the screening
method.
The Consensus development meeting
Procedure
The meeting comprised the following groups of par-
ticipants: A consensus committee (Appendix 1)1, re-
sponsible for the conduct and reporting of the consen-
sus meeting, expert speakers providing background in-
formation (Appendix 2)1, and an audience of profes-
sionals representing all relevant parties (Appendix 3).
In addition, foreign experts in the field of CRC screen-
ing participated in the discussions.
The consensus questions were defined in advance on
the basis of interviews with different representatives
or stakeholders of the government, the Health Coun-
1Conflicts of interest were recorded and filed.
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Fig. 1. Approximate cohort composition for 1 million individuals. Abbreviations in the figure: HR = high risk; F+ = positive family history;
CRC = colorectal cancer; HP = hyperplastic polyp; AD = adenoma. Numbers are approximates taken from European literature.
cil of the Netherlands, screening organisations, health
insurance companies, with ethical, screening, econom-
ical and biobank experts, radiologists, pathologists,
gastroenterologists and general practitioners organisa-
tions. A pre-consensus was established in favour of the
introduction of population screening using FOBT. This
was used as a starting point to define questions on im-
plementation and future research.
In order to investigate the essential requirements for
implementation of population screening using FOBT,
an extended list of criteria for population screening ini-
tially issued by Wilson and Jungner has been assessed.
Invited expert speakers were assigned to answer ques-
tions about fulfilment of criteria, gaps in knowledge
and potential improvements of FOBT screening in a
structured lecture during the meeting.
A set of questions was divided over a number of ex-
perts in sessions dedicated to “Organisation Aspects”
and “Medical and Technical Aspects” and “Future De-
velopments”.
To guide the discussions, a diagram was prepared
concerning cohort composition per million individuals
(Fig. 1) and an organisation flow chart was provided
(Fig. 2).
The outcomes of the workshop sessions were sum-
marised in draft documents that were reported in a ple-
nary session and the conclusions reached were sub-
jected to the consensus procedure. Voting instruments
were available, but their use was not necessary.
A writing committee has finalised this report.
General questions
1. What are the data from international investi-
gations that indicate that FOBT screening for
CRC fulfils the (extended) criteria of Wilson and
Jungner?
2. Which aspects would be a serious threat to start a
nation-wide FOBT screening in the Netherlands
in 2–3 years?
(a) Specific national aspects preventing extrapo-
lation of international research?
(b) Rate limiting steps (beyond 2–3 years) in or-
ganisation?
3. Which aspects form an opportunity for a quick/
smooth introduction of nation-wide FOBT screen-
ing?
(a) Existing organisations/screening facilities/
harmonisation of all cancer screening;
(b) Already available protocols/experiences; e.g.
from other screening programmes.
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Fig. 2. Concept flow chart. Abbreviations in the figure: ScO = screening organisation; GP = general practitioner; S = screening individual;
HP = hyperplastic polyp; CRC = colorectal cancer; AD = adenoma.
4. To obtain the best protocol for evidence-based
screening and best practice for follow-up, which
aspects
(a) should be further investigated in 1–2 years;
(b) require a decision by experts based on pres-
ently available evidence;
(c) should be subject of flanking research during
screening for continued improvement.
5. How should future research on new methods
be organised in relation to the planned national
screening?
(a) National or regional data- and bio-banking;
(b) Regional centres of excellence.
6. For each consensus topic an underlying question
is: “What is the role of ZonMw and other re-
search organisations such as The Dutch Cancer
Society, CVZ, etc. in addressing the research top-
ics”, or more in general “what needs to be done,
and who is responsible”.
7. Which working parties or project groups should
be defined to prepare a consensus on specific top-
ics in the coming 2–3 years?
General screening criteria
As criteria for implementation of screening we used
an extended list based on Wilson and Jungner’s (1968)
[14] original and WHO criteria, and additional criteria
on ethical (National Council for Public Health, 1994)
[10] and practical (Hanselaar, 2002) [3] issues.
The general screening criteria listed below were sup-
plied to all participants. The numbers refer to criteria
numbering in the text.
1. The condition sought should be an important
health problem for the individual and commu-
nity.
2. There should be an accepted treatment or useful
intervention for patients with the disease.
3. The natural history of the disease should be ad-
equately understood.
22 M. de Visser et al. / Report on the Dutch consensus development meeting
4. There should be a latent or early symptomatic
stage.
5. There should be a suitable and acceptable screen-
ing test or examination. (The test must be ac-
ceptable for the target population.)
6. Facilities for diagnosis and treatment should be
available.
7. There should be an agreed policy for referring
for further examination and whom to treat as pa-
tients.
8. Treatment started at an early stage should be of
more benefit than treatment started later.
9. The cost should be economically balanced in re-
lation to possible expenditure on medical care
as a whole.
10. Case finding should be a continuing process and
not a once only project.
11. The time between test and result and between
result and treatment must be as short as possi-
ble.
12. The recruitment procedure should not limit peo-
ple in their freedom to participate or not in the
screening programme.
13. Potential participants should receive adequate
information about pro and cons of participation.
Benefits and risks should also be well known to
health care providers.
14. Public education should promote a broad acces-
sibility of the programme. It should however not
include a moral pressure effect.
15. There should be quality assurance (QA) and
quality control (QC) procedures for the whole
screening programme.
16. Screening programmes are concerted actions
meeting organisational and managerial require-
ments.
Consensus statements about the extended Wilson
and Jungner (W&J) criteria2
W&J 1. The condition sought should be an important
health problem for the individual and community.
Consensus: CRC is an important health problem for
the individual and community. In 2001, 9206 cases
were diagnosed with CRC and this number is expected
to increase to 13835 in 2015. In 2003, 4.429 died from
CRC and this number is expected to increase in 2015
to 5305 in 2015. Overall five years survival is 55%. It
is of equal importance in both genders [8].
2The meeting was recorded: both presentations and discussion.
The records are kept by ZonMw.
W&J 2: There should be an accepted treatment or
useful intervention for patients with the disease.
Consensus: There are accepted treatments/interven-
tions for patients with malignancies and adenomas.
Active surveillance after treatment is defined, but not
based on extensive evidence. It is proposed to decide
to initially follow guidelines as they are. Further inter-
ventions after removal of hyperplastic polyps are not
generally indicated at present.
W&J 3: The natural history of the disease should be
adequately understood.
Consensus: The natural history of the disease is ad-
equately understood for invasive CRCs and for adeno-
mas, but not completely.
W&J 4: There should be a latent or early symptomatic
stage.
Consensus: There is an early stage that can only be
detected by screening.
W&J 5: There should be a suitable and acceptable
screening test or examination. (The test must be
acceptable for the target population.)
Consensus: FOBT screening is a suitable and ac-
ceptable method for population screening for the near
future (<2–3 years). Based on experience in other Eu-
ropean countries, a compliance rate of at least 60% can
be expected.
W&J 6: Facilities for diagnosis and treatment should
be available.
Consensus: A nationwide screening programme is
expected to generate at least 15,000 extra colono-
scopies per year. The necessary adaptation of the ca-
pacity and quality of diagnostic and therapeutic inter-
ventions within 2–3 years is feasible provided adequate
funding is made available.
W&J 7: There should be an agreed policy for
referring for further examination and whom to treat
as patients.
Consensus: All individuals with a positive FOBT
will be offered colonoscopy. There are agreed treat-
ment and surveillance protocols for patients with ade-
nomas/CRCs.
W&J 8: Treatment started at an early stage should be
of more benefit than treatment started later.
Consensus: Scientific evidence clearly shows that, in
the case of CRC, early detection and treatment leads to
more benefit than treatment that has started later.
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W&J 9: The cost should be economically balanced in
relation to possible expenditure on medical care as a
whole.
Consensus: Extrapolations of cost-effectiveness ra-
tios of other European countries indicate that it is eco-
nomically sensible to perform FOBT screening in the
Netherlands. This favourable cost effectiveness ratio
remains present down to a participation level of ap-
proximately 25% of the approached target population.
W&J 10: Case finding should be a continuing process
and not a once only project.
Consensus: FOBT screening should be nationwide
and bi-annual. The infrastructure will be maintained
for a period of at least 10 years.
W&J 11: The time between test and result and
between result and treatment must be as short as
possible.
Consensus: The time between test and result will be
in the order of days (1 week). In case of a positive
FOBT, there should be timely access to colonoscopy
(preferably within three weeks). This is essential for
acceptance of screening among target populations. The
waiting time between result of colonoscopy and treat-
ment/further intervention should be in accordance with
the standards for regular care.
W&J 12: The recruitment procedure should not limit
people in their freedom to participate or not in the
screening programme.
Consensus: The recruitment procedure is organised
by the national screening management according to
established legal and ethical standards ensuring free
choice of individuals.
W&J 13: Potential participants should receive
adequate information about pro and cons of
participation. Benefits and risks should also be well
known to health care providers.
Consensus: The information procedure for individ-
uals is the responsibility of the national screening or-
ganisation and will be carried out in line with current
national and European screening programmes, and will
be performed according to established ethical stan-
dards ensuring free choice of individuals. People will
be empowered to make an informed choice.
W&J 14: Public education should promote a broad
accessibility of the programme. It should however not
include a moral pressure effect.
Consensus: Public education is the responsibility of
the national screening organisation and will be carried
out according to established ethical standards.
W&J 15: There should be quality assurance (QA) and
quality control (QC) procedures for the whole
screening programme.
Consensus: It is the responsibility of the national
screening management to complete the set-up of a
quality system including both quality assurance and
quality control before the screening starts.
W&J 16: Screening programmes are concerted
actions meeting organisational and managerial
requirements.
Consensus: Yes, this is accomplished by having a
national screening management.
General conclusion: All criteria from the extended
list of Wilson and Jungner have already been fulfilled
or could be fulfilled within 2–3 years. Consequently,
a national population screening should be implemented
and carried out in line with current national and Euro-
pean cancer screening programmes.
Start of FOBT population screening after 2–3
years
General advise
It is advised, based on all available evidence, to
perform population screening bi-annually and with a
lower age limit of 50 and an upper age limit of 74 (the
exact age range to be decided within 2–3 years based
upon further research on cost-effectiveness, feasibility
and resources).
Action lists or agenda’s (<2–3 years)
The first action to be taken is instalment of a
‘national screening management’ by the Minister of
Health. In addition, CVZ, ZonMw, and the Dutch Can-
cer Society will establish an expert committee to work
out the action list, and to set priorities for research and
organisation for the coming 2–3 years for the imple-
mentation of population screening.
(A) Organisational agenda (<2–3 years)
The organisational actions that have to be taken to
implement FOBT screening are listed in Table 1.
For reference purposes a concept organogram of a
national screening organisation is given in Fig. 3.
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Table 1
List of organisational actions
Action By whom Remarks
Rapid identification of who will be the
national screening management and assurance
of smooth transition process
Minister of Health, Welfare and
Sport
Funding and long term estimates of screening
costs
CVZ
Draft implementation programme set-up National screening
management∗
Use experiences from national and
international screening programmes, and the
results of the Dutch implementation study.
Set-up of specialised colonoscopy centres for
the follow-up of screening. The funding for
this should come out of the regular health care
funds.
CBO
Preparation of screening organisations under
supervision of the national screening
managements
National screening
management
Feedback needed by professional
organisations (GPs, GEs, budget makers,
patients, individuals participating in screening,
general public).
Process control
Communication to the general public, the
media, and to health care professionals
National screening
management
ZonMw for research projects
Develop communication plans to effectively
bring the message about screening across, and
empower the public to make an informed
choice.∗∗
Information and guidelines for health care
professionals
Inform insurers in order to obtain guarantee of
reimbursement for treatment.
Monitoring of programme, and management
of information
Expert committee (CVZ,
ZonMw, The Dutch Cancer
Society)
Monitor side effects of the programme. Find
characteristics of non-compliant group
Establishment of research goals for the next
2–3 years
Expert committee (CVZ,
ZonMw, The Dutch Cancer
Society)
Working out of logistics of the primary
process of screening
Screening organisations Define the maximum intervals between
screening and colonoscopy, without interfering
with the regular care of CRC patients.
Define and set up reporting procedures.
Quality Working group set-up National screening
management in collaboration
with screening organisations.
Quality programme for other screening
programmes needed as well
Design of Database (all data from people to be
invited)
Pilot project Develop (bioinformatics) research tools as
add-ons to regular screening programme.
Decide on whether database is part of or
linked to the biobank
Can it be paid out of the diagnosis treatment
code?
Biobank should be part of the research
programme, is not prerequisite for screening
programme.
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Table 1
(Continued)
Action By whom Remarks
Provision of sufficient facilities for
colonoscopy for FOBT positive individuals.
Ministry of Health, Welfare
and Sport, CVZ, ZN, Dutch
Society of Gastroenterologists
Set up training facilities for nurse endoscopists
Nurse Practitioner Training Institutes to be
involved.
Exploration of legal issues concerning
screening programme.
National screening
management
Exploration of the role of the GP in the
screening process
National screening management
Evaluation Independent organisation Outcome: Can one improve the whole system?
Continuous evaluation programme
∗National screening management has until now been done by CVZ. This will change in the near future, therefore in the ‘by whom’ list, ‘National
Screening Management’ is mentioned next to CVZ.∗∗This may involve reconsideration and possible adjustment of (standard) informed consent norms, in case ‘full informed consent’ appears
unattainable.
Fig. 3. Concept organogram of a national screening management. #It is proposed to form the expert committee as soon as possible to work on
the organisational and research agendas.
(B) Research agenda (<2–3 years)
The research agenda, without priorities, for the com-
ing 2–3 years before implementation of FOBT screen-
ing is listed below.
– Studies on different FOBT methods to address:
(a) acceptance by the individual; (b) possible dif-
ferences in sensitivity and specificity; (c) sim-
plicity and costs of the screening method (au-
tomation?); (d) possibilities to adjust cut-off val-
ues for positive scores to temporarily reduce in-
flow in follow-up procedures (issuing from the
Amsterdam–Nijmegen implementation study).
The Erasmus MC is already dealing with cost ef-
fectiveness calculations for the various tests, in-
cluding cut-off values.
– Feasibility studies with respect to adaptation of
the capacity and quality of diagnostic and thera-
peutic intervention facilities.
– Communication studies (effectiveness of different
messages and tools) to explore whether people are
really empowered to make an independent choice,
and whether messages are understandable and ac-
ceptable for different population groups.
– CRC awareness studies and campaign among
general public and health care professionals.
– Comparison of models aiming at improvement of
compliance.
– For the purpose of bio- and databanking, estab-
lishing in advance whether additional tests will af-
fect compliance.
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– Study on whether or not to include the age group
of 50–55 yrs in population screening in the future.
Research agenda for continued improvement of the
FOBT-based screening
The question was put forward whether or not and
how, in a time span of 10–15 years, efforts should be
made to improve faeces-based population screening. It
was suggested to evaluate and discuss improvements
and procedures in cooperation with all stakeholders,
including patient representatives.
Firstly, it was proposed to explore the performance
and cost effectiveness of faecal tests additional to
FOBT, such as tests for DNA hypermethylation, mul-
tiple point mutations or specific proteins. An impor-
tant strategy in establishing new tests is gain of knowl-
edge of tumours, which lack mutations by faecal DNA
testing. New tests should be compared with results of
screening in different age groups with FOBT only.
Enhancement of the specificity with new methods,
for instance a CD44 (protein) test or imaging tech-
niques may improve the definition of negative results
preceding colonoscopy.
Secondly, new tests and combinations have to be
compared with the ‘gold standard’ (colonoscopy)
aimed at reduction of the number of false positive
FOBTs. As colonoscopy is a taxing procedure, a com-
parison of CT colonography with standard colonoscopy
in FOBT positives, could yield an alternative reference
standard.
Thirdly, to maximize the effectiveness of screening
it should be identified why some cancers are missed
by colonoscopy. The understanding of the contribution
of flat adenoma to the development of carcinoma is
important in this regard. In addition, an improved un-
derstanding of the biology of colorectal carcinogene-
sis is required including model studies. Identification
of adenomas with a high risk of progressing to cancer
can increase specificity. Methods to detect these high-
risk adenomas either with imaging or biomarkers are
desired. Study into the difference in the sensitivity of
colonoscopy to detect CRC in the left or the right part
of the colon, might lead to improvements.
Fourthly, research and training needs to be focused
on quality assurance and quality control of existing
procedures. Aspects include: (a) Training of endo-
scopist specialists; (b) Introduction of nurse endo-
scopists; (c) Evaluation of the training programme;
(d) Development of protocols for performance of endo-
scopies; and (e) Development of a task force that sets
standards.
Fifthly, the screening enables identification of fac-
tors for future risk profiling, e.g. environmental and ge-
netic factors.
Data collection in the follow-up of FOBT screen-
ing could provide additional evidence for the degree
of effectiveness of the present surveillance for various
situations and experimental protocols may (regionally)
evaluate other modalities.
Interval cancers provide an opportunity for retro-
spective analysis of risk elements recorded in the
screening. It may reveal the relative incidence of
rapidly developing adenomas as well as other factors.
This would require additional information, including
family history.
The aforementioned potential improvements in sce-
narios should be modelled and selected for experimen-
tal evaluation. Similarly, such procedures can be used
for:
– Assessment of changes in cost effectiveness due
to expected changes in cohort composition, cumu-
latively increasing surveillance after each screen-
ing round, increase of registration of high-risk
groups circumventing screening.
– Assessment of the effects of e.g. over-the-counter
FOBT tests, or open access of screening.
– Assessment of effects of combinations of FOBT
with infrequent endoscopic/imaging screening.
Consensus: Repeated FOBT screening shows sufficient
specificity (∼98%) and limited sensitivity (∼50%) and
leaves room for improvement. This improvement is not
to be expected from the FOBT itself. New faecal tests
with high sensitivity are being developed.
Research agenda/questions for possible future
(10–15 years) replacement of FOBT screening
The question was put forward whether or not and
how, in a time span of 10–15 years, efforts should be
made to evaluate replacement of the FOBT test. The
following topics were considered of relevance for fur-
ther evaluation:
(A) Multi-biological-variables testing on faeces
Other faecal tests can detect the presence of adeno-
mas and malignancies with DNA/RNA and/or protein-
analysis. In view of the multiformity of biological de-
viations, a panel of tests will be needed to achieve sub-
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stantial coverage of the phenotypes. The performance
of the following tests should be compared with FOBT:
(a) DNA hypermethylation test; (b) Multiple point mu-
tation tests; (c) Protein tests (Note that this list is not
comprehensive).
An important strategy in establishing new tests is
further research for additional mutations linked to col-
orectal cancer.
(B) Endoscopic procedures
New endoscopic developments should be tested.
These include:
– Magnetic markers for colonoscope guidance;
– Wide-angle colonoscopy for improved adenoma
detection;
– Self-propulsion colonoscope;
– Video capsule colonoscopy;
– Fluorescence endoscopy;
– Magnification endoscopy;
– Colouring techniques to enhance diagnostic sen-
sitivity (chromendoscopy).
(Note that this list is not comprehensive.)
(C) Virtual imaging procedures
The most promising virtual imaging method is CT
colonography, as moderate to good sensitivity and
good specificity have been reported in low-prevalence
populations. Further research is needed into radiation
dose in relation to bowel preparation.
Computer-assisted detection is a promising develop-
ment with regard to test characteristics and cost effec-
tiveness.
Molecular tagging may in the future further enhance
the performance of virtual imaging.
Consensus: Replacement of the FOBT should be
evaluated in case its future improvements (see previous
agenda) are unsatisfactory, and/or in case more ac-
ceptable methods for the screening of the target popu-
lation are developed and could be implemented in pop-
ulation screening.
Research infrastructure
The availability of screening data and biological
specimens in banks and the possibility of the coupling
of these with follow-up data would create a research
infrastructure.
The following topics were raised:
– In the forthcoming two years, a study should be
performed to evaluate the possibility of the de-
velopment of a modified faeces collection device
that allows additional tests on faeces as well as
biobanking of this material.
– Arrangements can be made to store biological
material for prolonged periods of time (>10
years) to cover follow-up periods.
– The exact questions that can be asked and an-
swered should be identified beforehand (within
2 years) to define the database- and biobank-
characteristics.
– Access to and ownership of database- and biobank
should be defined beforehand.
– A biobank should contain additional biological
material other than faeces.
– A biobank should be a national organisation,
probably with regional storage facilities.
– Attention should be paid to ways to obtain a struc-
tured report (including pathology) for subjects
with positive FOBT test results.
– Communication with different countries should
be intensified:
∗ Harmonize agendas with respect to research is-
sues;
∗ Improve compatibility of different ‘banks’.
Consensus: A project group should be formed to de-
fine the infrastructure (linking, extra data) and poten-
tial research (and patient care) questions within two
years.
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